Stockscreener 앱 받기
3.83
2.54%
-0.10
Lantern Pharma Inc 주식(LTRN)의 최신 뉴스
Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast - Barchart.com
IBN Announces Latest Episode of The BioMedWire Podcast - GlobeNewswire
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Panna Sharma, CEO of AI-Driven Biotech Focused on Challenging & Rare Cancers, Lantern Pharma Inc. (LTRN) - GlobeNewswire Inc.
Lantern Pharma Inc. At Decision Level — Rebound or Resistance2025 Buyback Activity & Comprehensive Market Scan Reports - beatles.ru
Does Lantern Pharma Inc. align with a passive investing strategyJuly 2025 Selloffs & Technical Pattern Recognition Alerts - beatles.ru
Sentiment analysis tools applied to Lantern Pharma Inc.July 2025 Gainers & Weekly Breakout Opportunity Watchlist - Newser
How liquid is Lantern Pharma Inc. stockJuly 2025 Volume & Weekly Return Optimization Plans - خودرو بانک
Can Lantern Pharma Inc. disrupt its industryQuarterly Portfolio Summary & High Accuracy Swing Trade Signals - خودرو بانک
Can Lantern Pharma Inc. grow without dilution2025 Retail Activity & Stock Portfolio Risk Management - 더경남뉴스
Is Lantern Pharma Inc. stock trending bullishPortfolio Performance Summary & Verified Momentum Stock Watchlist - خودرو بانک
Lantern Pharma Inc. stock volume spike explainedTrade Risk Assessment & AI Powered Market Entry Ideas - Newser
Lantern Pharma Inc. stock chart pattern explained2025 Fundamental Recap & High Accuracy Investment Signals - Newser
Can Lantern Pharma Inc. lead its sector in growthQuarterly Trade Summary & AI Enhanced Execution Alerts - خودرو بانک
Hoth Therapeutics shares fall 2.24% premarket after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
How sentiment analysis helps forecast Lantern Pharma Inc.Portfolio Return Report & Growth-Oriented Investment Plans - Newser
Using data tools to time your Lantern Pharma Inc. exitJuly 2025 Reactions & High Accuracy Investment Signals - Newser
Hoth Therapeutics shares fall 1.49% after-hours after adopting Lantern Pharma's AI-driven drug development tool. - AInvest
Lantern Pharma (NASDAQ: LTRN) Completes FDA Type C Meeting, Gains Guidance for Planned Pediatric CNS Cancer Trial - The Globe and Mail
Lantern Pharma shares fall 1.52% intraday after FDA meeting and Hoth Therapeutics partnership. - AInvest
AI-Driven Drug Development: Hoth Therapeutics and Lantern Pharma’s Strategic Partnership to Revolutionize CNS Therapies - AInvest
Lantern Pharma's PredictBBB.ai Platform to Drive Next-Gen Drug Development with Hoth Therapeutics Partnership - AInvest
Hoth Therapeutics Taps Lantern Pharma's PredictBBB.ai Platform -- Breakthrough AI With 94% Accuracy Driving Next-Gen Drug Development - WV News
Detecting support and resistance levels for Lantern Pharma Inc.CEO Change & Smart Swing Trading Alerts - Newser
What data driven models say about Lantern Pharma Inc.’s future2025 Breakouts & Breakdowns & Safe Entry Zone Identification - Newser
Will breakout in Lantern Pharma Inc. lead to full recoveryBear Alert & Fast Moving Stock Trade Plans - Newser
Lantern Pharma Receives FDA Guidance for Pediatric CNS Cancer Trial of AI-Discovered Therapy - citybuzz -
Automated trading signals detected on Lantern Pharma Inc.Market Movement Recap & Detailed Earnings Play Alerts - Newser
Lantern Pharma announces completion of Type C meeting with FDA - MSN
Lantern Pharma receives FDA feedback on pediatric brain cancer trial - Investing.com
Lantern Pharma Completes FDA Type C Meeting, Advances Pediatric CNS Cancer Trial with FDA Guidance - AInvest
Lantern Pharma Announces Completion of Type C Meeting with FDA, Providing Clarity on Regulatory Pathway for Pediatric CNS Cancer Trial - Business Wire
Top chart patterns to watch in Lantern Pharma Inc.July 2025 Review & Daily Chart Pattern Signals - Newser
What is Lantern Pharma Inc.’s book value per shareWeekly Profit Report & Risk Controlled Daily Trade Plans - خودرو بانک
How high can Lantern Pharma Inc. stock goMarket Sentiment Summary & Daily Profit Focused Stock Screening - Newser
Market reaction to Lantern Pharma Inc.’s recent newsWeekly Stock Analysis & Risk Managed Investment Strategies - Newser
How to integrate Lantern Pharma Inc. into portfolio analysis toolsJuly 2025 Weekly Recap & Fast Gain Stock Trading Tips - Newser
Will Lantern Pharma Inc. price bounce be sustainableWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
What machine learning models say about Lantern Pharma Inc.Fed Meeting & Accurate Entry/Exit Alerts - Newser
Does Lantern Pharma Inc. show high probability of reboundJuly 2025 Levels & Weekly High Return Opportunities - Newser
Is Lantern Pharma Inc. a cyclical or defensive stock2025 Market Trends & Weekly Market Pulse Alerts - خودرو بانک
Custom strategy builders for tracking Lantern Pharma Inc.Weekly Trend Summary & Target Return Focused Picks - Newser
Is Lantern Pharma Inc. vulnerable to short sellersBond Market & Low Volatility Stock Recommendations - خودرو بانک
Aug Rallies: What is the next catalyst for Lantern Pharma Inc.Market Volume Report & Safe Entry Trade Reports - خودرو بانک
Using Bollinger Bands to evaluate Lantern Pharma Inc.M&A Rumor & Stock Portfolio Risk Control - Newser
Can Lantern Pharma Inc. reach resistance levels soon2025 Market Trends & Fast Gaining Stock Strategy Reports - خودرو بانک
0.93%
0.10%
자본화:
|
볼륨(24시간):